Open Access Highly Accessed Open Badges Research article

Comparison of AMG 416 and cinacalcet in rodent models of uremia

Sarah Walter12, Amos Baruch13, Shawn T Alexander1, Julie Janes14, Eiketsu Sho15, Jin Dong16, Qun Yin17, Derek Maclean1*, Dirk B Mendel18, Felix Karim1 and Randolph M Johnson1

Author Affiliations

1 Amgen Inc, 1120 Veterans Blvd., South San Francisco, CA 94080, USA

2 Present address: Labrys Biologics, San Mateo, CA, USA

3 Present address: Genentech, South San Francisco, CA, USA

4 Present address: Calithera Biosciences, South San Francisco, CA, USA

5 Present address: Kunming Biomedical, Kunming, China

6 Present address: MedImmune, Hayward, CA, USA

7 Present address: Sutro Biopharma, South San Francisco, CA, USA

8 Present address: MedImmune, Gaithersburg, MD, USA

For all author emails, please log on.

BMC Nephrology 2014, 15:81  doi:10.1186/1471-2369-15-81

Published: 19 May 2014



AMG 416 is a novel peptide agonist of the calcium-sensing receptor (CaSR). This report describes the activity of AMG 416 in two different rodent models of uremia, compared in each case to cinacalcet, an approved therapeutic for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis.


AMG 416 was administered as a single intravenous (IV) bolus in a severe, acute model of renal insufficiency (the ā€œ1K1Cā€ model) and plasma parathyroid hormone (PTH) and serum calcium levels were monitored for 24 hours. In a chronic, less severe model of renal dysfunction, the 5/6 nephrectomy (5/6 Nx) model, AMG 416 was administered as a once-daily IV bolus for 28 days. Both studies included a control (vehicle) group and a comparison cinacalcet group (po dosing at 30 mg/kg and 10 mg/kg for the 1K1C and 5/6 Nx studies, respectively).


Administration of AMG 416 by IV bolus injection into rats with acute renal dysfunction (1K1C model) resulted in a sustained reduction in plasma PTH from the initial elevated values. Following a single IV bolus (0.5 mg/kg), AMG 416 caused a substantial drop in PTH levels which remained approximately 50% below their initial level at 24 hrs. In the same model, oral treatment with cinacalcet (30 mg/kg) resulted in an acute drop in PTH which almost returned to the starting level by 24 hours after dosing. In the 5/6 Nx chronic uremia model, daily IV dosing of AMG 416 over 4 weeks (1 mg/kg) resulted in a sustained reduction in PTH, with approximately 50% of the initial level observed 48 hours post treatment throughout the study. Cinacalcet treatment (10 mg/kg) in the same model resulted in acutely lowered plasma PTH levels which returned to placebo levels by 24 hours post-dose. Consistent with the reductions in plasma PTH, reductions in serum calcium were observed in both AMG 416- and cinacalcet-treated animals.


As a long-acting CaSR agonist suitable for administration by the IV route, AMG 416 is a potential new therapy for the treatment of CKD patients with SHPT receiving hemodialysis.

Calcium-sensing receptor; Secondary hyperparathyroidism (SHPT); Chronic kidney disease (CKD); Uremic rat model; AMG 416